News

"Sparsentan has the potential to be a significant medicine, and could transform the treatment of FSGS," said John Higgins, President and Chief Executive Officer of Ligand Pharmaceuticals. "The

This new agreement includes a cross-license of intellectual property (IP) on four disease targets, providing each company with exclusive RNA therapeutic license rights for two programs. The agreement

The collaboration, which is being facilitated by Johnson & Johnson Innovation, Boston, focuses on the discovery and development of candidate molecules for the treatment of inflammatory diseases. Under

Under this agreement, Fast Forward will provide funding to Bionure for the late-preclinical development of BN201 to enable IND filling to support the Phase 1 clinical study in

The patent broadly and specifically covers the company’s dopamine D2/D3 drug candidates, their pharmaceutical compositions, and their use to treat a number of important gastrointestinal conditions in humans,

The deal approved by the boards of directors from both companies will see Shire pay $46 per share in cash for NPS, which has expertise in gastrointestinal (GI)

As part of the deal, Precision’s NanoAssemblr platform will be used to manufacture GMP batches to support clinical trials and commercial development for RNA medicines developed using Arcturus’

Under the deal, discovery efforts on an undisclosed regulatory membrane protein will be driven by Proteros over a two-year period to meet predefined milestones, while Bayer will be

The acquisition is centered on development of the UK firm’s Phase II clinical candidate CNV1014802, which has showed clinical activity in proof of concept trials for trigeminal neuralgia